Abstracts tagged "practice improvement and rheumatoid arthritis (RA)"

Abstract Number: 2470 • 2016 ACR/ARHP Annual Meeting
Treat to Target: Theoretical Agreement Vs Daily Applicability
Leonardo Romeiro¹, Dalton Torigoe², Claiton Brenol³, Roberto Ranza⁴, Lícia M. H. Mota⁵, Manoel Bertolo⁶, Max Freitas⁷, José Tupinambá⁸, Ivanio Pereira⁹, Lucila Fronza¹⁰ and Ieda Maria Magalhães Laurindo¹¹, ¹Rheumatology, UNESA, Rio de Janeiro, Rio de Janeiro, Brazil, ²Faculdade de Medicina da Santa Casa de Misericordia, São Paulo, Brazil, ³Rua Cabral, 764 – Apto 302, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ⁵Hospital Universitário de Brasília - UnB, Brasília, Brazil, ⁶INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil, ⁷Pathology, Federal University of Ceara, Fortaleza, Brazil, ⁸Universidade Federal do Piaui, Teresina, Brazil, ⁹Rheumatology, Universidade do Sul de Santa Catarina, Florianopolis, Brazil, ¹⁰CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Brazil, ¹¹Internal Medicine - Rheumatology, Faculdade de Medicina da Universidade Nove de Julho, São Paulo, Brazil
Background/Purpose: Treat to target (T2T) strategy has been widely recognized as effective and leading to better outcomes. There have been no questions regarding its theoretical…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].